hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06291363 id: 2024-3612 briefTitle: Impact of Administration of Esmolol on Nociception Level-guided Control of Nociception. acronym: ESMONOL overallStatus: NOT_YET_RECRUITING date: 2024-04-04 date: 2025-03-03 date: 2025-03-04 date: 2024-03-04 date: 2024-03-25 name: Ciusss de L'Est de l'Île de Montréal class: OTHER briefSummary: This study aims to evaluate esmolol's perfusion impact during induction and maintenance of general anesthesia, using Nociception-Level-guided control of nociception, in adult patients undergoing laparoscopic and lower abdominal surgery, on intraoperative remifentanil consumption and postoperative pain in the Post-Anesthesia Care Unit. conditions: Opioid Use, Unspecified conditions: Anesthesia conditions: Nociceptive Pain studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups of patients randomized into Group "ESMOLOL" for esmolol and group "Standard of Care" for a total of 64 participants. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Randomization will be done prior to the entrance in the OR, the day of the surgery. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 64 type: ESTIMATED name: Esmolol Hydrochloride name: Saline measure: Intra operative remifentanil administration measure: The NOL Index variation before and after orotracheal intubation and first surgical incision measure: The mean intraoperative blood pressure and heart rate measure: doses and time weighted of norepinephrine (mg); ephedrine (mg), glycopyrrolate (mg) and atropine (mg) measure: Total time with NOL value above > 25 measure: The total time and time weighted average of hypotension and/or bradycardia measure: The time to first analgesic requirement in PACU measure: The amount of morphine equivalent consumption measure: The intensity of pain at rest and under stress measure: Postoperative nausea and vomiting (PONV) and antiemetics use measure: The time spent in PACU sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Maisonneuve-Rosemont Hospital - CIUSSS de l'Est de l'Île de Montréal city: Montréal-Est state: Quebec zip: H1T2M4 country: Canada name: Pascal Laferrière-Langois, MD FRQS role: CONTACT phone: +1-819-432-5847 email: pascal.laferriere-langlois@umontreal.ca name: Pascal Laferrière-Langois, MD FRQS role: PRINCIPAL_INVESTIGATOR lat: 45.63202 lon: -73.5075 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-02-26 uploadDate: 2024-03-21T17:38 filename: Prot_000.pdf size: 732855 hasResults: False
nctId: NCT06291350 id: 23-AOI-05 briefTitle: Peridontal and Intestinal Microbiota in Patients With Gingival Scarring Pemphigoid acronym: MICROPC overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-03-15 date: 2026-09-15 date: 2024-03-04 date: 2024-03-15 name: Centre Hospitalier Universitaire de Nice class: OTHER briefSummary: Patients suffering from Mucous Membrane Pemphigoid with desquamative gingivitis (MMPg) generally present a more degraded periodontal condition compared with controls. Bullous disease could represent a risk factor for plaque-induced periodontal disease, and vice versa.
Indeed, the dysbiotic periodontal microbiota could aggravate the gingival damage specific to MMP, either directly by activating inflammatory pathways, or indirectly by degrading cellular and matrix components. On the other hand, areas of erosive gingiva generated by the autoimmune process could increase the virulent power of periodontal pathobionts, by representing accessible, nutrient-rich connective surfaces. Moreover, in recent years, bacterial studies based on a high-throughput metagenomic approach have suggested the existence of a relationship between the oral and intestinal microbiota in patients with degraded periodontal conditions and suffering from autoimmune inflammatory diseases (inflammatory bowel disease, acute graft-versus-host disease). This relationship can also be envisaged in MMPg patients who meet the conditions that allow this type of pathological process to occur: autoimmune disease; disruption of the gingival epithelial barrier in erosive gingival areas (increasing the risk of antigen exposure); large amounts of thick plaque; degraded periodontal condition with the presence of numerous periodontal pockets from which periodontopathogenic bacteria can translocate intra-tissularly and cause distant adverse consequences.
The main aim of this observational, multicentre, case-control, matched study is to compare the composition of the periodontal microbiota between MMPg patients and control patients (arm 2 and arm 3). The secondary objectives are to compare the composition of periodontal and intestinal microbiota in cases and control patients (arm 2 and arm 3), to compare periodontal microbiota composition in cases and control patients (arm 2) according to periodontitis severity, and to compare gut microbiota composition between cases and control patients (arm 2 and arm3). To date, no such study exists. conditions: Pemphigoid, Benign Mucous Membrane conditions: Gingivitis Hyperplastic studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 45 type: ESTIMATED name: Plaque sampling and stool collection name: periodontal examination measure: composition of the periodontal microbiota measure: Compare the composition (name and number of bacterial colonies) of periodontal in MMP and control patients (arm 2 and arm 3). measure: Compare the composition (name and number of bacterial colonies) intestinal microbiota in MMP and control patients (arm 2 and arm 3). measure: Compare (name and number of bacterial colonies) periodontal microbiota composition in MMP and control patients (arm 2) according to periodontitis severity (non-severe/severe) measure: Compare (name and number of bacterial colonies) gut microbiota composition between MMP and control patients (arm 2 and arm3) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nice University Hospital city: Nice zip: 06000 country: France name: Sophie DRIDI, PUPH role: CONTACT phone: 04 92 03 30 07 email: dr.sm.dridi@free.fr name: Rachida Yatimi role: CONTACT phone: 04 92 03 30 07 email: yatimi.r@chu-nice.fr name: Sophie DRIDI role: PRINCIPAL_INVESTIGATOR lat: 43.70313 lon: 7.26608 facility: Paris hospital Pitié Salpetrière (APHP) city: Paris zip: 75013 country: France name: Juliette ROCHEFORT role: CONTACT phone: 0142178416 email: juliette.rochefort@aphp.fr name: Juliette ROCHEFORT role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Paris hospital Bretonneau (APHP) city: Paris zip: 75018 country: France name: Anne-Laure AJEIL role: CONTACT phone: 0153111800 email: anne-laure.ejeil@aphp.fr name: Anne-Laure AJEIL role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06291337 id: Pro2019001483 id: 10-204Mc type: OTHER domain: Rutgers IRB briefTitle: Ibuprofen Inhibits Human Sweet Taste overallStatus: COMPLETED date: 2020-06-01 date: 2023-09-01 date: 2023-09-30 date: 2024-03-04 date: 2024-03-04 name: Rutgers, The State University of New Jersey class: OTHER name: Monell Chemical Senses Center briefSummary: The sweet taste receptor, TAS1R2-TAS1R3, is expressed both orally, where it signals sweet taste, and extraorally in the intestine and pancreas, where it may affect glucose absorption and metabolism. Recently, ibuprofen and naproxen have been identified to inhibit human T1R3 when heterologously expressed in cells. In the present study, the initial objective was to determine if ibuprofen and naproxen inhibit interactions of sugars with human sweet taste receptor under normal, physiological conditions. Ten healthy participants were asked to rate sweetness intensity for a range of sweet stimuli (sucrose, fructose, sucralose) after a prerinse of ibuprofen, naproxen or water. Both ibuprofen and naproxen inhibited sweet taste intensity in a dose-dependent manner. In association studies, ibuprofen use has been linked to preserved metabolic function, as its use is correlated with lower rates of Alzheimer's disease, diabetes and colon cancer. Here the investigators present a potential novel pathway for systemic ibuprofen to impact these metabolic diseases. conditions: Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants conditions: Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy Participants studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: We are testing individual sin a within subject control for their sweet taste ratings of sugars without and with oral rinses of ibuprofen and naproxen. primaryPurpose: BASIC_SCIENCE masking: NONE count: 32 type: ACTUAL name: Inhibition of Sweet Taste by Ibuprofen Oral Rinses name: Inhibition of Sweet Taste by Naproxen Oral Rinses measure: Sweet taste ratings measure: Sugar detection thresholds sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Food Science and Nutritional Sciences city: New Brunswick state: New Jersey zip: 08901 country: United States lat: 40.48622 lon: -74.45182 hasResults: False
nctId: NCT06291324 id: IRB00103472 id: LCI-SUPP-CRF-WATD-001 type: OTHER domain: Atrium Health briefTitle: WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-12-15 date: 2025-12-15 date: 2024-03-04 date: 2024-03-04 name: Wake Forest University Health Sciences class: OTHER name: Atrium Health Levine Cancer Institute briefSummary: The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients. conditions: Pancreatic Cancer conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 46 type: ESTIMATED measure: Adherence and acceptability measure: Theme measure: Heart rate variability (HRV) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Levine Cancer Institute city: Charlotte state: North Carolina zip: 28204 country: United States name: Alicia Patrick role: CONTACT phone: 980-292-1746 email: alicia.patrick@atriumhealth.org name: Dori Beeler, PhD role: PRINCIPAL_INVESTIGATOR lat: 35.22709 lon: -80.84313 hasResults: False
nctId: NCT06291311 id: MT_NIPP-HPV_ERBE briefTitle: Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants overallStatus: RECRUITING date: 2023-12-27 date: 2024-06 date: 2025-12 date: 2024-03-04 date: 2024-03-04 name: University Hospital Tuebingen class: OTHER briefSummary: This is a prospective, single-center, observational proof-of-principle clinical trial at the Department of Women's Health of the University Hospital Tübingen. conditions: HPV Infection conditions: Cervical Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Cold physical Plasma name: Control group measure: HPV eradication rate measure: Correlation of HPV Genotyping measure: HPV-Quality-of-Life (HPV-QoL) measure: Tissue Tolerance and Compatibility of NIPP Treatment measure: Detection of Intracellular Molecular Plasma Mechanisms sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Tuebingen, Department of Women's Health status: RECRUITING city: Tuebingen zip: 72076 country: Germany name: Martin Weiss, Dr. med. role: CONTACT phone: +4970712982211 email: martin.weiss@med.uni-tuebingen.de lat: 48.52266 lon: 9.05222 hasResults: False
nctId: NCT06291298 id: STUDY006542 briefTitle: Novel Adaptive Cognitive Training in Autistic Adults With Co-occurring Insomnia overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2025-04-01 date: 2024-03-04 date: 2024-03-04 name: University of South Florida class: OTHER briefSummary: The proposed study will test the usability and feasibility of a novel cognitive training (COGMUSE) for autistic adults with co-occurring insomnia (COGMUSE- AUT). Participants (n=15) will complete the cognitive training intervention for 60 minutes per day, 3 times per week for 6 weeks at home totaling to 18 hours. Weekly check-ins will be conducted by study staff over Teams to ensure adherence to the treatment and provide an opportunity for qualitative feedback on the game sessions played. During these 6 weeks, participants will fill out daily (2x/day) electronic sleep diaries and wear an actigraph device (GENEActiv). GENEActiv is a watch-like device that monitors light and movement activity. conditions: Autism Spectrum Disorder conditions: Insomnia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Pilot test COGMUSE-AUT in a small sample of autistic adults with co-occurring insomnia on primary and secondary outcomes. primaryPurpose: OTHER masking: NONE count: 15 type: ESTIMATED name: COGMUSE-AUT measure: Objective Cognition-National Institute of Health Toolbox measure: Objective Slee-Daily Actigraphy measure: Subjective Sleep- Electronic Daily Sleep Diaries measure: Insomnia Severity Index measure: Sleep Habits Questionnaire measure: Pre-Sleep Arousal measure: WHO Quality of Life-BREF measure: Mood measure: Depression measure: Adaptive Behavior Assessment System (ABAS-III) measure: Game-related experience (completed during intervention) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06291285 id: NN7533-7587 id: U1111-1285-7491 type: OTHER domain: World Health Organization (WHO) briefTitle: A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People overallStatus: NOT_YET_RECRUITING date: 2024-02-27 date: 2024-07-11 date: 2024-07-11 date: 2024-03-04 date: 2024-03-04 name: Novo Nordisk A/S class: INDUSTRY briefSummary: This study will look at two different oral formulations and compare them. The medicine in the study is called NDec and it is a combination of two medicines (decitabine and tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease, a rare blood disease. The purpose of the study is to compare the absorption of two different NDec versions (a tablet and a capsule). Participant will either get first the tablet and then the capsule, or the other way around. The order in which participant get them is decided by chance. The study will last for about 12 to 45 days depending on the wash-out period between the two stays in the clinic and from recruitment to the first study day. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: Decitabine-THU name: Decitabine-THU measure: AUC0-inf,DEC,SD: Area under the plasma decitabine concentration-time curve after a single dose measure: AUC0-inf,THU,SD: Area under the plasma tetrahydrouridine concentration-time curve after a single dose measure: Cmax,DEC,SD: Maximum plasma concentration of decitabine after a single dose measure: Cmax,THU,SD: Maximum plasma concentration of tetrahydrouridine after a single dose measure: t½,DEC,SD: Terminal half-life for decitabine after a single dose measure: t½,THU,SD: Terminal half-life for tetrahydrouridine after a single dose measure: tmax,DEC,SD: Time to maximum observed plasma decitabine concentration after a single dose measure: tmax,THU,SD:: Time to maximum observed plasma tetrahydrouridine concentration after a single dose measure: Maximum change from pre dose in dNA methyltransferase 1 (DNMT1) protein expression after a single dose measure: Maximum change from pre dose in cytidine deaminase (CDA) activity after a single dose sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT facility: ICON-Salt Lake City city: Millcreek state: Utah zip: 84124 country: United States lat: 40.68689 lon: -111.87549 facility: Profil Institut für Stoffwechselforschung GmbH city: Neuss zip: 41460 country: Germany lat: 51.19807 lon: 6.68504 hasResults: False
nctId: NCT06291272 id: FMHS 328-0723 briefTitle: Effect of Methylcellulose or Psyllium on Fermentation of inUlin Assessed USing MRI acronym: RUFUS overallStatus: RECRUITING date: 2023-10-15 date: 2024-06-30 date: 2024-10-30 date: 2024-03-04 date: 2024-03-04 name: University of Nottingham class: OTHER name: Quadram Institute Bioscience briefSummary: Our challenge is to understand how fibre interacts with whole-gut function to alter colonic fermentation of FODMAPs. We will exploit the recent availability of a range of food grade modified celluloses which can form gels at body temperature to perform human studies to explore whether the beneficial effect of psyllium is unique or will be found with all gelling substances (4). We are currently performing the COCOA2 study using a modified methylcellulose (results awaited). We now wish to perform a pilot study to image what happens in the colon when methylcellulose is ingested to enable us to plan the next step in our research programme. conditions: Colon, Irritable studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: 3 way cross -over primaryPurpose: BASIC_SCIENCE masking: TRIPLE maskingDescription: Opaque plastic bags containing test meals prepared by some one not involved in analysis pf results whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 18 type: ESTIMATED name: Psyllium name: Methylcellulose name: Inulin name: Maltodextrin measure: colonic gas volume measure: colonic gas volume at 6 hours measure: Breath hydrogen measure: Oro-cecal transit time measure: 24 hour breath hydrogen sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nottingham Digestive Disease Centre status: RECRUITING city: Nottingham state: Nottinghamshire zip: NG7 2UH country: United Kingdom name: Alaa Alhasani, BSc role: CONTACT phone: 01159429924 email: alyaa11@exmail.nottingham.ac.uk name: Robin Spiller role: CONTACT phone: +447824328319 email: robin.spiller@nottingham.ac.uk lat: 52.9536 lon: -1.15047 hasResults: False
nctId: NCT06291259 id: CTO 4081 briefTitle: Mpox Prospective Observational Cohort Study acronym: MPOCS overallStatus: RECRUITING date: 2022-06-21 date: 2024-09 date: 2024-09 date: 2024-03-04 date: 2024-03-04 name: Unity Health Toronto class: OTHER briefSummary: The goal of this multicentre prospective observational cohort study is to shed light on the following unknowns:
The study is divided into Part 1 (corresponding to the acute phase of illness) and Part 2 (corresponding to the convalescent phase of the illness); part 2 will be optional. Participants enrolled during the acute phase of illness will complete part 1 of the study and will be invited to participate in Part 2 as well. Part 1 of the study will include the following three core components, at baseline and weekly (±3 days) until one week after the resolution of all symptoms (i.e. one week after complete healing of skin lesions):
Other optional components for all participants include in the Image Atlas, an online database of clinical images of mpox, designed to provide clinicians and community members of what mpox looks like in real life, and the biobank, which will store research samples for potential future studies. conditions: Monkeypox studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 250 type: ESTIMATED measure: Description of clinical manifestation measure: Psychosocial impact measure: Transmission-related aspects of mpox infection measure: Virologic aspects of mpox infection over time sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: BC Centre For Excellence status: RECRUITING city: Vancouver state: British Columbia zip: V6Z 1Y6 country: Canada name: Brody Lyon role: CONTACT phone: 604-682-2344 phoneExt: 66230 email: blyons@bccfe.ca name: Mark Hull, MD role: PRINCIPAL_INVESTIGATOR lat: 49.24966 lon: -123.11934 facility: Unity Health Toronto status: RECRUITING city: Toronto state: Ontario zip: M5B 1T8 country: Canada name: Shreya Shah role: CONTACT phone: 416-360-4000 phoneExt: 77312 email: shreya.khera@unityhealth.to name: Darrell HS Tan role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 facility: University Health Network status: RECRUITING city: Toronto state: Ontario country: Canada name: Asmaa Mabrouk role: CONTACT phone: 416-340-4800 phoneExt: 2240 email: Asmaa.mabrouk@uhn.ca name: Sharon Walmsley, MD role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06291246 id: 23-1823 id: K12TR004416-01 type: NIH link: https://reporter.nih.gov/quickSearch/K12TR004416-01 briefTitle: Expediting Access to Services for Equity (EASE) acronym: EASE overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-06-30 date: 2026-06-30 date: 2024-03-04 date: 2024-03-04 name: University of North Carolina, Chapel Hill class: OTHER name: National Center for Advancing Translational Sciences (NCATS) briefSummary: The goal of this clinical trial is to assess whether telehealth-based Family Navigation (FN) expedites enrollment (e.g., reduces time in days) in community-based autism intervention for Black toddlers under the age of 3 after their initial diagnosis of autism.
Researchers will compare participants who receive family navigation to participants who receive the standard of care (educational materials) to see if family navigation outperforms the standard of care. conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 86 type: ESTIMATED name: Virtual Family Navigation name: Educational Materials measure: Time to initiation of autism specific intervention measure: Caregiver Well-Being Score measure: Child's Developmental Functioning Score measure: Child's Adaptive Functioning Score measure: Appropriateness of Intervention Score measure: Feasibility of Intervention Score measure: Acceptability of Intervention Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Carolina Institute for Developmental Disabilities city: Carrboro state: North Carolina zip: 27510 country: United States lat: 35.91014 lon: -79.07529 hasResults: False
nctId: NCT06291233 id: HUM00236812 id: 1R01MH132656-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01MH132656-01 briefTitle: A Hybrid Effectiveness-Implementation Randomized Clinical Trial (RCT) of Virtual Interview Training for Autistic Transition-Age Youth overallStatus: ENROLLING_BY_INVITATION date: 2024-03-01 date: 2026-03-01 date: 2026-03-01 date: 2024-03-04 date: 2024-04-05 name: University of Michigan class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: The purpose of the study is to see if an internet job interview training program can help people that have autism improve interview skills and access to jobs.